Alicaforsen
Explore a selection of our essential drug information below, or:
Identification
- Generic Name
- Alicaforsen
- DrugBank Accession Number
- DB06224
- Background
Not Available
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- Alicaforsen
Pharmacology
- Indication
Investigated for use/treatment in crohn's disease and ulcerative colitis.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Alicaforsen selectively inhibits ICAM‑1 gene expression. Over-expression of ICAM‑1 occurs in a wide variety of inflammatory disorders, including ulcerative colitis (UC), pouchitis and tissues in the eye, gastrointestinal teact, lungs and skin. UC is an inflammatory bowel disease of the colon, a part of the large intestine, and pouchitis is an inflammation of the surgically constructed internal pouch created in UC patients when their diseased colons are removed. [ISIS Pharmaceutical Website] Alicaforsen is a RNase H dependent phosphorothioate-modified antisense oligodeoxynucleotide inhibitor which shuts down specific sequences of intracellular adhesion molecule 1 (ICAM1) mRNA and thus production of ICAM1, which prevents the inflammatory response. ICAM is a cell surface glycoprotein (immunoglobulin superfamily) which facilitates leukocyte adhesion and antigen presentation in the intestinal mucosa. Alicaforsen hybridizes the oligonucleotide strand with the target mRNA to suppress expression of ICAM1.
Target Actions Organism AIntercellular adhesion molecule 1 other/unknownHumans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
- Product Ingredients
Ingredient UNII CAS InChI Key Alicaforsen sodium 4TWN6SZB8W 331257-52-4 Not applicable
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- J8435V445B
- CAS number
- 185229-68-9
References
- General References
- Miner PB Jr, Geary RS, Matson J, Chuang E, Xia S, Baker BF, Wedel MK: Bioavailability and therapeutic activity of alicaforsen (ISIS 2302) administered as a rectal retention enema to subjects with active ulcerative colitis. Aliment Pharmacol Ther. 2006 May 15;23(10):1427-34. [Article]
- Gewirtz AT, Sitaraman SV: Technology evaluation: alicaforsen (Isis). Curr Opin Mol Ther. 2005 Jun;7(3):273-81. [Article]
- Fefferman DS, Farrell RJ: Making sense of antisense: ISIS 2302 (alicaforsen) in the treatment of pouchitis. An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule-1, in the treatment of chronic, unremitting pouchits. Inflamm Bowel Dis. 2004 Jul;10(4):487-8. [Article]
- Link [Link]
- External Links
- Wikipedia
- Alicaforsen
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample data3 Completed Treatment Crohn's Disease (CD) 2 somestatus stop reason just information to hide 3 Completed Treatment Pouchitis 1 somestatus stop reason just information to hide 2 Completed Treatment Ulcerative Colitis 2 somestatus stop reason just information to hide 1 Completed Basic Science Inflammatory Bowel Diseases (IBD) 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Targets
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Other/unknown
- General Function
- ICAM proteins are ligands for the leukocyte adhesion protein LFA-1 (integrin alpha-L/beta-2). During leukocyte trans-endothelial migration, ICAM1 engagement promotes the assembly of endothelial apical cups through ARHGEF26/SGEF and RHOG activation
- Specific Function
- integrin binding
- Gene Name
- ICAM1
- Uniprot ID
- P05362
- Uniprot Name
- Intercellular adhesion molecule 1
- Molecular Weight
- 57824.785 Da
References
- Zhou Y, Zhang Y, Zhao D, Yu X, Shen X, Zhou Y, Wang S, Qiu Y, Chen Y, Zhu F: TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751. [Article]
Drug created at March 19, 2008 16:17 / Updated at August 26, 2024 19:21